Coverage Determination Request Form - End-Stage Kidney Disease (ESRD) / Dialysis-Related Drugs (Medicare B vs. D)

Request Information (required)

This request is:

☐ **Expedited* (Urgent)** (decision within 24 hours)

☐ **Standard (Non-Urgent)** (decision within 72 hours)

*If the requestor or prescriber believe that waiting 72 hours for a standard decision could seriously harm the member's life, health, or ability to regain maximum function, an expedited (fast) decision can be requested. If the prescriber indicates that waiting 72 hours could seriously harm the member's health, a decision will automatically be made within 24 hours. If the prescriber's support for an expedited request is not obtained, the request will be reviewed to determine if a fast decision is required.

Please Note: All information below is required to process this request. Any information that is incomplete or illegible will delay the review process. If the request is asking for an EXCEPTION, the prescriber MUST provide a statement supporting the request and the request cannot be processed without one. Please submit all **FORMULARY EXCEPTION** requests on the standard **CMS COVERAGE DETERMINATION** form. Requests that are subject to PRIOR AUTHORIZATION (or any other utilization management requirement), may require supporting information.

Member Information (required)			Prescriber Information (required)		
Member Name:			Prescriber Name:		
Member Insurance ID #:			NPI # :		Specialty:
Date of Birth:			Office Phone:		
Member Phone:			Office Fax:		
Member Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:

Requestor Information (required if not requested by the member or prescriber)

An individual other than the member or prescriber (such as a family member or friend) may make a request on behalf of the member provided that the individual is a representative. **Documentation must be attached** showing the individual's authority to represent the member (a completed Authorization of Representation Form CMS-1696 or a written equivalent). For more information on appointing a representative, contact the plan or 1-800-Medicare.

Requestor Name:		Requestor Phone:
Requestor Address:		Relationship to Member:
City:	State:	Zip:

Medication Information (required)

Indicate Medication Requested: (NOTE: Drugs below are a representative list, only. See plan formulary to verify coverage status.) ☐ Indicate Drug: _____	Quantity Prescribed:	Dosage Form:
Strength & Route of Administration:	Directions for Use (including frequency and expected length of therapy):	

B vs. D Primary Billing Determination (required)

Requests submitted with Chronic Kidney Disease (CKD) diagnosis are subject to BvD Primary Billing Determination for the coverage categories listed below (select one and answer the question below):

☐ Access Management: Drugs used to ensure access by removing clots from grafts, reverse anticoagulation if too much medication is given, and provide anesthetic for access placement. This category includes drugs such as ARGATROBAN, heparin sodium (porcine), heparin (porcine) in sodium chloride and heparin sod (porcine) in D5W.

☐ Bone and Mineral Metabolism: Drugs used to prevent/treat bone disease secondary to dialysis. This category includes drugs such as calcitriol (ROCALTROL), calcitonin (salmon), doxercalciferol, ibandronate sodium, pamidronate disodium, paricalcitol (ZEMPLAR), cinacalcet hydrochloride (SENSIPAR), and zoledronic acid (ZOMETA).

☐ Cellular Management: Drugs used for deficiencies of naturally occurring substances needed for cellular management. This category includes levocarnitine (CARNITOR / CARNITOR SF / MCCARNITINE).

☐ Anemia Management: Drugs used to treat anemia in a member diagnosed with end-stage renal disease (ESRD) who currently requires dialysis. This category includes epoetin alfa inj. (EPOGEN, PROCRIT), darbepoetin alfa inj. (ARANESP), epoetin alfa-epbx inj (RETACRIT), and methoxy PEG-epoetin beta inj. (MIRCERA).

☐ Antiemetic; Anti-infective (including antibacterial and antifungal drugs); Antipruritic; Anxiolytic; Excess Fluid Management; Fluid and Electrolyte Management (including volume expanders) and Pain Management: Drugs in these categories *may* be considered ESRD-related if they are prescribed for conditions that arise secondary to dialysis treatment.

☐ **Is the requested drug being used to treat an ESRD/Dialysis-related condition in a member diagnosed with end-stage renal disease (ESRD) *who currently requires Dialysis*? (ICD 10 Code: N18.6)**

☐ Yes ***(Covered under the ESRD Prospective Payment System (PPS), drug must be supplied by dialysis facility)***

OR ☐ No ***(Complete Part D Coverage Determination Criteria section below)***

Part D Coverage Determination Criteria (required)

The following requirements need to be met before this drug can be covered by the Part D plan. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

Which condition is the drug being used for?

☐ Prescribed for the treatment of anemia due to Chronic Kidney Disease (CKD) in a member not on dialysis. **(ARANESP, EPOGEN and RETACRIT ONLY)**

☐ Prescribed for the treatment of anemia in a member with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. **(ARANESP, EPOGEN and RETACRIT ONLY)**

☐ Prescribed for the treatment of anemia due to zidovudine administered at less than or equal to (≤) 4,200 mg/week in a member with human immunodeficiency virus (HIV)-infection with endogenous serum erythropoietin levels of less than or equal to (≤) 500 mUnits/mL. **(RETACRIT and EPOGEN ONLY)**

☐ Prescribed to reduce the need for allogeneic red blood cell (RBC) transfusions in a member with perioperative hemoglobin greater than (>) 10 to less than or equal to (≤) 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. **(RETACRIT and EPOGEN ONLY)**

☐ Indicate diagnosis: _____ ICD-10 Code (s): _____

Please Note: If the condition being treated with the requested drug is a symptom e.g. anorexia, weight loss, shortness of breath, chest pain, nausea, etc., provide the diagnosis causing the symptom(s) if known. This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either:*

- Approved by the Food and Drug Administration (FDA) – that is, that the FDA has approved the drug for the diagnosis or condition for which it is being prescribed.
- Supported by any of the following reference books – American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and/or the USPDI or its successor.

This drug requires the following prior authorization criteria be met in order to be covered under the Part D plan:

☐ **FOR ARANESP ONLY:** Member has tried and failed or was intolerant to RETACRIT **OR** EPOGEN.

Are there any other comments, diagnoses, symptoms, medications tried or failed (including dates of drug trials and results of previous drug trials), drug allergies and/or any other pertinent information the physician feels is important to this review? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Exception Requests (optional)

If the request is not for a prior authorization, please indicate the request type:

The prescriber **MUST** provide a statement supporting the request. Requests cannot be processed without one.

☐ The member has been using a drug that was previously included on the plan's list of covered drugs, but is being removed or was removed from the list during the plan year.

☐ The request is for an exception to the plan's limit on the number of pills (quantity limit) the member can receive so that the member can get the number of pills the prescriber prescribed.

☐ The drug plan charges a higher copayment for the drug the prescriber prescribed than it charges for another drug that treats the member's condition, and the member wants to pay the lower copayment.

☐ The member has been using a drug that was previously included on a lower copayment tier, but is being moved to or was moved to a higher copayment tier.

☐ The drug plan charged the member a higher copayment for a drug than it should have.

☐ The member wants to be reimbursed for a covered prescription drug that they paid for out of pocket.

Do you believe one or more of the prior authorization requirements should be waived? ☐ Yes ☐ No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

Would this medication likely be the most effective option for this member? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Is the member currently being treated for the condition(s) requiring the requested drug? ☐ Yes ☐ No

(If yes, please explain the member's current drug regimen for the condition(s) below)

_____

_____

_____

If the member is currently using this medication, would changing the current regimen likely result in adverse effects for the member? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Are there any concerns for a drug interaction with the addition of the requested drug to the member's current drug regimen? ☐ Yes ☐ No (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)

_____

_____

_____

Are there any FDA noted contraindications to the requested drug? ☐ Yes ☐ No (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)

_____

_____

_____

Submission Information (required)

Signature: _____ **Date:** _____

Please Note:

- This request may be denied or dismissed unless all required information is received.
- The prescriber's office will receive a response via fax.
- For urgent requests, please call the phone number listed below.
- For real time submission 24/7 please visit the secure prescriber portal on our plan's website for the appropriate form and instructions on how to submit your request.
- Requests can also be initiated via phone or the form may be sent via fax or mail:

Phone Number: (866) 270-3877
Fax Number: (855) 668-8552
Mailing Address: ATTN: PRIOR AUTHORIZATION
P.O. Box 1039
Appleton, WI 54912-1039

Authorization Period: 1 Year.

PLEASE FAX COMPLETED FORM TO: 855-668-8552